The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be ...

CMPS has benefited from positive phase 3 trial results and positive political developments since my last article. Click here ...

Compass Pathways (CMPS), on Wednesday, said the U.S. Food and Drug Administration (FDA) has accepted its Investigational New ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...

Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND ...

Shares of Compass Pathways Plc continue to trade within highly speculative territory, closing the week at $5.23 with a marginal gain of $0.01. Beneath this surface-level stability lies a fundamental ...

Investing.com - Oppenheimer has upgraded Compass Pathways (NASDAQ:CMPS) from Perform to Outperform, setting a price target of $15.00 based on the potential of its psilocybin therapy for ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Compass Pathways Plc is conducting a ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaborati ...

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help ...